Corline Biomedical (Sweden) Insiders
| CLBIO Stock | SEK 7.24 0.16 2.26% |
Corline Biomedical employs about 10 people. The company is managed by 2 executives with a total tenure of roughly 24 years, averaging almost 12.0 years of service per executive, having 5.0 employees per reported executive. Breaking down Corline Biomedical's management performance can provide insight into the firm performance.
| Henrik Nittmar Insider Chief Officer |
| Pr Tufveson Insider Chief Officer |
Corline |
Corline Biomedical Management Team Effectiveness
Corline Biomedical's management efficiency ratios could be used to measure how well Corline Biomedical manages its routine affairs as well as how well it operates its assets and liabilities.Corline Biomedical Workforce Comparison
Corline Biomedical AB is rated third in number of employees category among its peers. The total workforce of Biotechnology industry is currently estimated at about 89.0. Corline Biomedical retains roughly 10.0 in number of employees claiming about 11% of stocks in Biotechnology industry.
The company has Profit Margin (PM) of 0.02 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.02 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.02. Corline Biomedical Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Corline Biomedical Price Series Summation is a cross summation of Corline Biomedical price series and its benchmark/peer.
Corline Biomedical Notable Stakeholders
A Corline Biomedical stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Corline Biomedical often face trade-offs trying to please all of them. Corline Biomedical's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Corline Biomedical's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Henrik Nittmar | Chief Officer | Profile | |
| Pr Tufveson | Chief Officer | Profile |
About Corline Biomedical Management Performance
The success or failure of an entity such as Corline Biomedical often depends on how effective the management is. Corline Biomedical management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Corline management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Corline management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications. The company was founded in 1991 and is based in Uppsala, Sweden. Corline Biomedical operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 9 people.
Please note, the imprecision that can be found in Corline Biomedical's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Corline Biomedical AB. Check Corline Biomedical's Beneish M Score to see the likelihood of Corline Biomedical's management manipulating its earnings.
Corline Biomedical Workforce Analysis
Traditionally, organizations such as Corline Biomedical use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Corline Biomedical within its industry.Corline Biomedical Manpower Efficiency
Return on Corline Biomedical Manpower
| Revenue Per Employee | 706.2K | |
| Revenue Per Executive | 3.5M | |
| Net Loss Per Employee | 692.2K | |
| Net Loss Per Executive | 3.5M |
Additional Tools for Corline Stock Analysis
When running Corline Biomedical's price analysis, check to measure Corline Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corline Biomedical is operating at the current time. Most of Corline Biomedical's value examination focuses on studying past and present price action to predict the probability of Corline Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corline Biomedical's price. Additionally, you may evaluate how the addition of Corline Biomedical to your portfolios can decrease your overall portfolio volatility.